Page 182 - FBL AR 2019-20

Fermenta Biotech Limited
Annual Report 2019-20

Consolidated Cash Flow Statement for the year ended March 31, 2020
( H in Lakhs )
Particulars March 31, 2020 March 31, 2019*
C. Cash flows from financing activities
Proceeds from long term borrowings 3,085.98 1,317.95
Repayment of long term borrowings (6,528.31) (759.92)
Net increase in short term borrowings 1,688.96 2,852.31
Finance costs (2,055.93) (2,042.78)
Repayment of Lease Liabilities (213.86) -
Dividends paid (597.16) (121.67)
Dividends distribution tax paid (124.42) (23.57)
Net cash generated from/(used in) financing activities (C) (4,744.74) 1,222.32
Net increase / (decrease) in cash and cash equivalents (A)+(B)+(C) (5,664.70) 598.57
Cash and cash equivalents at the beginning of the year 3,842.26 3,243.69
Cash and cash equivalents at the end of the year (1,822.44) 3,842.26
Components of cash and cash equivalents
Cash on hand 4.32 3.34
Balances with banks
In current accounts 747.13 1,174.10
Deposits with original maturity of less than 3 months - 2,899.06
Cash and cash equivalents (Refer note 17) 751.45 4,076.50
Cash credit and Bank overdraft facilities included under loans repayable on demand (2,573.89) (234.24)
(Refer note 28)
Total cash and cash equivalents considered for cash flows (1,822.44) 3,842.26

*(Refer note 1.2)
See accompanying notes 1 to 69 to the Consolidated financial statements
In terms of our report attached
For DELOITTE HASKINS & SELLS LLP For and on behalf of the Board of Directors of
Chartered Accountants Fermenta Biotech Limited (Formerly known as DIL Limited)

Rajesh K. Hiranandani Krishna Datla Satish Varma Prashant Nagre
Partner Managing Director Executive Director Chief Executive Officer

Sumesh Gandhi Srikant N. Sharma
Chief Financial Officer Company Secretary

Mumbai, August 28, 2020 Thane, August 28, 2020

180